SPRC SCISPARC LTD

SciSparc Gains Competitive Edge with Additional U.S. Patent Granted

SciSparc Gains Competitive Edge with Additional U.S. Patent Granted

This patent extends protection, adding to six other U.S. patents already granted

TEL AVIV, Israel, Nov. 08, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC), a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system (the “Company” or “SciSparc”), announced today that the U.S. Patent and Trademark Office has granted it a new patent - U.S. Patent No. 11,491,172, title: COMPOSITIONS AND METHODS OF POTENTIATING ANTIMICROBIALS (the “Patent”).

This patent further strengthens the Company’s intellectual property portfolio and protection of its core technologies, and in one of the most important markets in the world.

This is SciSparc’s seventh granted patent in the United States. Previously, the Company announced it has been granted additional patents in Australia, Japan and Israel. The Company's IP portfolio currently includes nine patent families and two trademarks.

About SciSparc Ltd. (NASDAQ: SPRC)

SciSparc Ltd. is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists. SciSparc’s focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company is currently engaged in the following drug development programs based on THC and/or non-psychoactive cannabidiol (CBD): SCI-110 for the treatment of Tourette Syndrome, for the treatment of Alzheimer's disease and agitation; SCI-160 for the treatment of pain; and SCI-210 for the treatment of autism spectrum disorder and status epilepticus.

Investor Contact:



Tel:



EN
08/11/2022

Underlying

SPRCSCISPARC LTD

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on SCISPARC LTD

 PRESS RELEASE
Free
SPRC SCISPARC LTD

SciSparc: NeuroThera Labs Granted U.S. Patent for Cannabinoid Technolo...

SciSparc: NeuroThera Labs Granted U.S. Patent for Cannabinoid Technology to Overcome Antimicrobial Resistance such as MRSA NeuroThera’s Proprietary Cannabinoid-Enhanced Platform Targets Antibiotic Resistance Using Approved Antimicrobials TEL AVIV, Israel, Feb. 02, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders, in which SciSparc holds a controlling interest of approxim...

February 2, 2026 1 EN
 PRESS RELEASE
Free
SPRC SCISPARC LTD

SciSparc Successfully Completes Acquisition of IP Portfolio, Advances ...

SciSparc Successfully Completes Acquisition of IP Portfolio, Advances Toward Immediate Commercialization SciSparc intends to target the global multi- billion dollar GERD device market TEL AVIV, Israel, Jan. 26, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a company engaged in clinical-stage pharmaceutical developments through its majority-owned subsidiary NeuroThera Labs Inc., announced today the closing of the acquisition of an IP portfolio of patents, trademarks and intellectual property rights for innovative endoscopic systems and medical cameras, ...

January 26, 2026 1 EN
 PRESS RELEASE
Free
SPRC SCISPARC LTD

SciSparc Signs Definitive Agreement to Acquire a Treasury of Patents f...

SciSparc Signs Definitive Agreement to Acquire a Treasury of Patents for the Endoscope Market- Entering Multi-Billion Dollar Opportunity SciSparc intends to commence commercialization of these patented technologies immediately following the transaction closing TEL AVIV, Israel, Jan. 13, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a company engaged in clinical-stage pharmaceutical developments through its majority-owned subsidiary NeuroThera Labs Inc., announced today the signing of a definitive agreement to acquire a treasury of patents, trademarks an...

January 13, 2026 1 EN
 PRESS RELEASE
Free
SPRC SCISPARC LTD

SciSparc Announces Receipt of Nasdaq Notification of Minimum Stockhold...

SciSparc Announces Receipt of Nasdaq Notification of Minimum Stockholders’ Equity Non-Compliance TEL AVIV, Israel, Jan. 12, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a company engaged in clinical-stage pharmaceutical developments through its majority-owned subsidiary NeuroThera Labs Inc., announced today that it has received a written notification (the “Notification Letter”) from the Listing Qualifications staff of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it is no longer in compliance with the minimum stockholders’ equity re...

January 12, 2026 1 EN
 PRESS RELEASE
Free
SPRC SCISPARC LTD

SciSparc: Neurothera Labs Granted Patent by Israeli Patent Office for ...

SciSparc: Neurothera Labs Granted Patent by Israeli Patent Office for its Proprietary Opioid-Based Patent Family to Enhance Pain Relief and Reduce Side Effects TEL AVIV, Israel, Dec. 30, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders, in which SciSparc holds a controlling interest of approximately 75%, announced that the Israel Patent Office has granted a patent for its ...

December 30, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch